Policy & Regulation
Transcell Oncologics Launches New Portfolio, Transtoxbio, for Testing COVID-19 Vaccines and Drug Candidates
1 July 2020 - - Indian life science company Transcell Oncologics has launched Transtoxbio, a portfolio for COVID-19 Vaccines and Drug candidates, the company said.

Transtoxbio offers a collection of human derived ethically immune configured progenitor cell/tissue platforms as human surrogate systems to support the growing community of pharma and preclinical research industry.

Their capacities takes pride in sourcing, isolating, and preserving the authenticity of all configured cell/tissue based systems with predictive powers needed to assist preclinical exploratory testings with discovery and development of druggable formulations.

According to the company, it is the only portfolio with specialised capabilities to test Bio/therapeutics (vaccine/drug candidates) induced species specific hematotoxicity, relevant transcriptomics, cytokine involved inflammatory pathways, Pulmonotoxicity on human surrogate in vitro models to predict their prognosis in clinical trials.


Related Headlines